Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 40, 2005, Pages 6288-6294

  Li, Gui Ping ^a   Zhang, Hui ^a   Zhu, Cheng Mo ^b   Zhang, Jian ^b   Jiang, Xu Feng ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Avidin biotin; Colon carcinoma; Radioimmunoimaging; Radioimmunotherapy

Indexed keywords

AVIDIN; BIOTIN; CARCINOEMBRYONIC ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PENTETIC ACID; SAMARIUM 153;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; CANCER GRAFT; CANCER INHIBITION; CANCER TRANSPLANTATION; COLON CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKOCYTE COUNT; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR NECROSIS; TUMOR VOLUME; XENOGRAFT;

EID: 29544437756     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i40.6288     Document Type: Article

References (32)

1. Bian HJ, Chen ZN, Deng JL. Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radioimmunoconjugate for hepatocellular carcinoma imaging. World J Gastroenterol 2000; 6: 348-352
2. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713
3. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100: 1891-1895
4. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28: 1294-1302
5. Paganelli G, Malcovati M, Fazio F. Monoclonal anribody pretargetting techniques for tumour localization: the avidin-biotin system International workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun 1991; 12: 211-234
6. Yao Z, Zhang M, Kobayashi H, Sakahara H,,Nakada I, Yamashina J, Konishi J. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 1995; 26: 837-841
7. Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meront M, Manani M, Vignali M, Siccardi AG, Fazio F. Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322-329
8. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Siccardi AG, Fazio F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5966
9. Paganelli G, Stella M, Zito F, Magnani P, De-Nardi P, Mangili F, Baratti D, Veglia F, Di-Carlo V, Siccardi AG, Fazio F. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med 1994; 35: 1970-1975
10. 64Cu for tumor imaging and therapy. J Nucl Med 2003; 44: 1284-1292
11. Modorati G, Brancato R, Paganelli G, Magnani P, Pavoni R, Fazio F. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol 1994; 78: 19-23
12. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44: 400-411
13. Axworthy DM, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97: 1802-1807
14. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002; 86: 207-212
15. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003; 30: 773-776
16. 153Sm for combined radioimmunoscintigraphy and radioimmunotherapy. J Nucl Med 1989; 30: 683-691
17. Hnatowich DJ, Childs RL, Lanteigne D, Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 1983; 65: 147-157
18. Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Scassellati GA, Epenetos AA. Intraperitoneal radio-localization of tumors pretargeted by biotinylated monoclonal antibodies. Int J Cancer 1990; 45: 1184-1189
19. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG, Fazio F. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996; 37: 967-971
20. Hamblett KJ, Kegley BB, Hamlin DK, Chyan MK, Hyre DE, Press OW, Wilbur DS, Stayton PS. A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem 2002; 13: 588-598
21. Kobayashi H, Sakahara H, Hosono M, Yao Z, Toyama S, Endo K, Konishi J. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med 1994; 35: 1677-1684
22. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 anti-body/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000; 6: 406-414
23. 99mTc-DTPA-bis-biotin in rat as-30D-hepatoma cells. Nucl Med Biol 2003; 30: 135-140
24. 211At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers. Clin Cancer Res 2003; 9 (10Pt 2): 3873S-3879S
25. 166Ho as a stable in vivo generator system. Int J Pharm 2003; 255: 129-138
26. 2 fragments by avidin-biotin a strategy. Nucl Med Biol 1999; 26: 57-62
27. Kraeber-Bodere F, Mishra A, Thedrez P, Faivre-Chauvet A, Bardies M, Imai S Le, Boterff J, Chatal JF. Pharmacokinetics and biodistribution of samarium-153-labeled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur J Nucl Med 1996; 23: 560-567
28. Rosebrough SF, Hartley DF. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J Nucl Med 1996; 37: 1380-1384
29. Kassis AI, Jones PL, Matalka KZ, Adelstein SJ. Antibody-dependent signal amplification in tumor xenografts after pretreatment with biotinylated monoclonal antibody and avidin or Streptavidin. J Nucl Med 1996; 37: 343-352
30. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review "of mice and men." Hybridoma 1997; 16: 101-107
31. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 1997; 38: 409-418
32. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94(4 Suppl): 1373-1381